An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease

Brief summary

The purpose of this study is to assess the efficacy and safety of lanabecestat compared with placebo administered for 104 weeks in the treatment of early Alzheimer´s disease. The study will test the hypothesis that lanabecestat is a disease-modifying treatment for participants with early Alzheimer´s disease, defined as the continuum of participants with mild cognitive impairment (MCI) due to Alzheimer´s disease and participants diagnosed with mild dementia of the Alzheimer´s type, as measured by change from baseline on the 13-item Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog13) score at week 104 in each of the 2 lanabecestat treatment groups compared with placebo.

Source: ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters. Not a U.S. Government endorsement.

Trial details

acronym

AMARANTH

status

TERMINATED

phase

PHASE2, PHASE3

study type

INTERVENTIONAL

enrollment

2218

sponsor

AstraZeneca

conditions

Alzheimer´s Disease

interventions

DRUG: Lanabecestat; DRUG: Placebo

start date

2014-09-30

start date type

ACTUAL

primary completion date

2018-10-04

has results

true

data source

ClinicalTrials.gov

data processed

2026-10-29T09:00:05

modifications

selected fields only; whitespace normalized; brief summary truncated to 2,000 characters